Call to arrange a consultation
+1 416 777 0888

Alexandre Lavoie

Associate

Alexandre received his J.D. Degree from the University of Ottawa in 2019. Prior to law school, Alexandre received a Bachelor of Science in Biomedical Sciences, with an emphasis in medicinal chemistry, also from the University of Ottawa. During law school, he volunteered at the Ottawa Legal Information Centre helping self-represented litigants navigate their way through the judicial system. Alexandre was also an active member of the Ottawa Law Review, being Executive Editor during his third year. He also participated in a moot court on language rights whereby he defended the rights of francophones in British Columbia.

Alexandre Lavoie

My recent cases

Actions under the  new Patented Medicines (Notice of Compliance) Regulations regarding Patent  No. 2,632,375 (diclofenac).

Actions under the  new Patented Medicines (Notice of Compliance) Regulations regarding Patent  No. 2,932,603 (diclofenac).

Actions under the  new Patented Medicines (Notice of Compliance) Regulations regarding Patent  No. 2,861,480 (trifluridine/tipiracil hydrochloride).

Actions under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,861,480; 2,914,999 and 2,985,006 (trifluridine/tipiracil).

Actions under the  new Patented Medicines (Notice of Compliance) Regulations regarding Patent  No. 2,534,024 (canagliflozin).

Actions under the  new Patented Medicines (Notice of Compliance) Regulations regarding Patent  No. 2,671,357 (canagliflozin).

Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,655,212 and 2,705,163 (vortioxetine).

Actions under the  new Patented Medicines (Notice of Compliance) Regulations regarding Patent  No. 2,851,588 (brexpiprazole).

Actions under the  new Patented Medicines (Notice of Compliance) Regulations regarding Patent  No. 2,602,247 (brexpiprazole).

Actions under the  new Patented Medicines (Notice of Compliance) Regulations regarding Patent  No. 2,832,157 (brexpiprazole).

Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,496,249 (linagliptin).

Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,557,801, 2,606,650, 2,751,833 and 2,813,661 (empagliflozin).

Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,738,367 (linagliptin).

Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,696,558 (linagliptin).

Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,782,179 (linagliptin).

Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,732,803 (linagliptin).

Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,649,922 (linagliptin).

Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,696,558 and 2,752,435 (empagliflozin).

Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,936,852, 2,485,143, 2,544,621 and 2,781,799 (riociguat)

Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,752,437 (linagliptin).

Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,845,553 (tenofovir alafenamide).

Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,845,553 and 2,990,210 (tenofovir alafenamide/emtricitabine).

Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,731,370 and 2,764,475 (selexipag).

Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,731,370 and 2,764,475 (selexipag).

Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,589,765, 2,589,921, 2,701,778, 2,741,312 and 2,873,044 (carfilzomib).

Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent Nos. 2,762,013 and 2,620,380 (pirfenidone)

Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,709,997 (pirfenidone)

Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,620,380 (pirfenidone)

Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,667,654 (pirfenidone)

Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,937,365 (pirfenidone)

Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,631,646 (pirfenidone)

Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,710,014 (pirfenidone)

Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,710,358 (pirfenidone)

Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,819,967 (pirfenidone)

Interested in joining the team?

We are always on the lookout for talented individuals.

View Careers